TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05874921: uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Sponsor: UroGen Pharma Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$14,599,200

Rescue Site Savings

+$9,655,800

Unlock Full NCT05874921 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05874921 Rescue Dossier →